{
    "id": "dbpedia_6613_2",
    "rank": 93,
    "data": {
        "url": "https://www.oncotypeiq.com/en-ca/breast-cancer/healthcare-professionals/oncotype-dx-breast-recurrence-score/interpreting-the-results",
        "read_more_link": "",
        "language": "en",
        "title": "Interpreting the Results",
        "top_image": "https://www.oncotypeiq.com-/media/project/precisiononcology/oncotypeiq/images/oiq_shareimage.jpg?rev=5ed137dc427243f896438b5270db2353",
        "meta_img": "https://www.oncotypeiq.com-/media/project/precisiononcology/oncotypeiq/images/oiq_shareimage.jpg?rev=5ed137dc427243f896438b5270db2353",
        "images": [
            "https://www.oncotypeiq.com/-/media/project/precisiononcology/oncotypeiq/images/logo/odx_endorsed_black_svg.svg?iar=0&rev=b7202e672df14a51be00b20a090e9ea6&hash=D5ABB8CF32C893FACD47D240B4242410",
            "https://www.oncotypeiq.com/-/media/project/precisiononcology/oncotypeiq/icons/metaanalysis2-tealbg2.png?h=160&iar=0&w=160&rev=eafbbf3edb424394a187b1110090caee&hash=91864528D06DEFAAC0C2F6C3254FEDB0",
            "https://www.oncotypeiq.com/-/media/project/precisiononcology/oncotypeiq/images/promo-images/call_center.jpg?h=264&iar=0&w=273&rev=80a3c5a17ad74be8a33e03ba53fadfef&hash=6A28BBFE0BC7F2BD03C7B53A106EA159",
            "https://www.oncotypeiq.com/-/media/project/precisiononcology/precisiononcology/oiq-reports/breast/breast-reports/ibc_node_negative_sample_report_page_1.png?h=1314&iar=0&w=1016&rev=10a9056bca5e4b2e8a0748fd78c00673&hash=0A2BAD7F0DD8CC32D2273A4CB1390A47",
            "https://www.oncotypeiq.com/-/media/project/precisiononcology/precisiononcology/oiq-reports/breast/breast-reports/ibc_node_negative_sample_report_page_2.png?h=1315&iar=0&w=1018&rev=0ed9e63453274068a532e119a5456ca2&hash=61A49B381E1353169574519D43CB4CB7",
            "https://www.oncotypeiq.com/-/media/project/precisiononcology/precisiononcology/oiq-reports/breast/breast-reports/ibc_node_negative_sample_report_page_3.png?h=1315&iar=0&w=1016&rev=fe39b2f90bb44168b49ce3733a28622a&hash=316860B562DFE23E472D609DA410A041",
            "https://www.oncotypeiq.com/-/media/project/precisiononcology/precisiononcology/oiq-reports/breast/breast-reports/exs14673_0424_en_int_n1-sample-report_page_01.png?h=1315&iar=0&w=1016&rev=896960bda1dd4073aa9163adf1d2cdab&hash=626037AB0DB1B3274183E48743933F73",
            "https://www.oncotypeiq.com/-/media/project/precisiononcology/precisiononcology/oiq-reports/breast/breast-reports/exs14673_0424_en_int_n1-sample-report_page_02.png?h=1315&iar=0&w=1016&rev=d966af54463d4b4f8f3cfa66ef200a5e&hash=DDA397E5D319976DCF3C9CD030A49839",
            "https://www.oncotypeiq.com/-/media/project/precisiononcology/oncotypeiq/images/logo/odx_brs_pos_svg.svg?iar=0&rev=b7590b1d7fce4c33abed066718d3ca3b&hash=BB596E61683F651CE18D77177AFD1746",
            "https://www.oncotypeiq.com/-/media/project/precisiononcology/oncotypeiq/icons/icon-case-study.png?h=161&iar=0&w=146&rev=d8c6f554687e4edbac555d3461ca5ad4&hash=CDC6533BAA40BB29E1DCE58747CF7082",
            "https://www.oncotypeiq.com/-/media/project/precisiononcology/oncotypeiq/images/logo/order-multicolor.png?h=160&iar=0&w=160&rev=db61fbbefcaa4ba9a36ac569884393dc&hash=6DFFE6FC92E256431C47C3932463B1FA",
            "https://www.oncotypeiq.com/-/media/project/precisiononcology/oncotypeiq/images/promo-images/call_center.jpg?h=264&iar=0&w=273&rev=80a3c5a17ad74be8a33e03ba53fadfef&hash=6A28BBFE0BC7F2BD03C7B53A106EA159"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "The Oncotype DX Breast Recurrence Score® report provides three points of clarity to aid in treatment decisions. Learn more.",
        "meta_lang": "en",
        "meta_favicon": "-/media/project/precisiononcology/oncotypeiq/icons/favicon.png?rev=4cfcd03475a24b6a965512352baa2c1c",
        "meta_site_name": "",
        "canonical_link": "//www.oncotypeiq.com/en-ca/breast-cancer/healthcare-professionals/oncotype-dx-breast-recurrence-score/interpreting-the-results",
        "text": "Recurrence Score Result\n\nPatients with a Recurrence Score result of 0-25 generally do not benefit from the addition of chemotherapy to endocrine therapy.2,3,6\n\nFor patients under 50 years of age there is some chemotherapy benefit (in terms of DRFI) for those with Recurrence Score result 16 and above.6\n\nPatients with Recurrence Score results 26–100 significantly benefit from the addition of chemotherapy to endocrine therapy.2,3\n\nRecurrence Score Result\n\nPost-menopausal patients with a Recurrence Score result of 0–25 do not benefit from the addition of chemotherapy to endocrine therapy.4,7\n\nPre-menopausal patients with Recurrence Score results of 0-25 have a 2.4% benefit (in terms of DRFI) from the addition of chemotherapy to endocrine therapy.8\n\nAll patients with Recurrence Score results 26-100 significantly benefit from the addition of chemotherapy to endocrine therapy.4"
    }
}